AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28673368 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administration
Number of subjects: 534
Study 28673368 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 534
Study 26843155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (SQ-LNSs)
Number of subjects: 869
Study 23771835 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance prior to aerobic training (RA)
Number of subjects: 26
Study 23771835 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance after aerobic training (AR)
Number of subjects: 26
Study 23771835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RA and AR
Number of subjects: 26
Study 21737178 — intervention group
Group type: EXPERIMENTAL
Intervention: CHG gel
Number of subjects: 32
Study 21737178 — intervention group
Group type: EXPERIMENTAL
Intervention: CHG disk
Number of subjects: 32
Study 21737178 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 19346443 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN (0.8 mg)
Number of subjects: 8
Study 19346443 — intervention group
Group type: EXPERIMENTAL
Intervention: PETN (80 mg)
Number of subjects: 8
Study 19346443 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN plus LA (600 mg)
Number of subjects: 8
Study 17688053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue injection after aspiration of more than 15 ml of CSF (Group A)
Number of subjects: 31
Study 17688053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue injection without CSF aspiration (Group B)
Number of subjects: 31
Study 15599679 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical health education lesson
Number of subjects: 1911
Study 15599679 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health education lesson)
Number of subjects: 1911
Study 12470133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette-related cues exposure (watching a videotape that presented cigarette-related cues and handling a cigarette)
Number of subjects: 40
Study 12470133 — intervention group
Group type: COMPARATOR
Intervention: Neutral object exposure (watching an educational (nature) videotape and handling a neutral object (pen))
Number of subjects: 40
Study 12470133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette-related cues exposure
Number of subjects: 40
Study 9718197 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoids (beclomethasone or budesonide) > or = 1500 microg/day for at least 12 months
Number of subjects: 53
Study 9718197 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior oral glucocorticoid exposure (OG)
Number of subjects: 53
Study 9718197 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoids (IG)
Number of subjects: 53
Study 9718197 — intervention group
Group type: EXPERIMENTAL
Intervention: Total duration of OG
Number of subjects: 53
Study 9718197 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone formation markers
Number of subjects: 53
Study 9718197 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenal androgen suppression
Number of subjects: 53
Study 9718197 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IG
Number of subjects: 53
Study 8110727 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid (0.9% normal saline)
Number of subjects: 107
Study 8110727 — intervention group
Group type: COMPARATOR
Intervention: Colloid (5% human serum albumin)
Number of subjects: 107
Study 2508527 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole for 8 weeks (L8 series)
Number of subjects: 504
Study 2508527 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole for 4 weeks (L4 series)
Number of subjects: 504
Study 2508527 — intervention group
Group type: COMPARATOR
Intervention: Placebo only (L0 series)
Number of subjects: 504
Study 2508527 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (both L4 and L8)
Number of subjects: 504
Study 2508527 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 504
Study 776209 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 1.0 mg
Number of subjects: 230
Study 776209 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 1.5 mg
Number of subjects: 230
Study 776209 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 2.0 mg
Number of subjects: 230
Study 776209 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 3.0 mg
Number of subjects: 230
Study 776209 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF2alpha 10.0 mg
Number of subjects: 230
Study 776209 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2
Number of subjects: 230
Study 776209 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF2alpha
Number of subjects: 230
Study 30391370 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month training interval
Number of subjects: 167
Study 30391370 — intervention group
Group type: COMPARATOR
Intervention: 3-month training interval
Number of subjects: 167
Study 30391370 — intervention group
Group type: COMPARATOR
Intervention: 6-month training interval
Number of subjects: 167
Study 30391370 — intervention group
Group type: COMPARATOR
Intervention: 12-month training interval
Number of subjects: 167
Study 27265488 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min passive rest
Number of subjects: 11
Study 27265488 — intervention group
Group type: COMPARATOR
Intervention: 20 min passive rest
Number of subjects: 11
Study 24851793 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative dose of pregabalin combined with a COX‐2 inhibitor
Number of subjects: 41
Study 24851793 — intervention group
Group type: COMPARATOR
Intervention: COX‐2 inhibitor only (Control)
Number of subjects: 41
Study 23146926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (10 mg)
Number of subjects: 238
Study 23146926 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers (bisoprolol 2.5 mg/day, carvedilol 12.5 mg/day, atenolol 50 mg/day)
Number of subjects: 238
Study 22172779 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day for 6 months
Number of subjects: 80
Study 22172779 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 80
Study 19223709 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin solutions
Number of subjects: 0
Study 17122576 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (loading dose of 1 mg followed by continuous infusion of 0.5 mg/h)
Number of subjects: 24
Study 17122576 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (as above)
Number of subjects: 24
Study 15098969 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinoids and antibiotics combination therapy
Number of subjects: 0
Study 11676995 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV based on nocturnal oximetry studies suggesting oxygen desaturation <90% for one cumulative minute (early intervention)
Number of subjects: 20
Study 11676995 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (NPPV based on FVC <50%)
Number of subjects: 20
Study 9640366 — intervention group
Group type: EXPERIMENTAL
Intervention: R alpha methylhistamine (RAMHA)
Number of subjects: 0
Study 9640366 — intervention group
Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 0
Study 9640366 — intervention group
Group type: COMPARATOR
Intervention: Thioperamide
Number of subjects: 0
Study 9640366 — intervention group
Group type: COMPARATOR
Intervention: Substance P
Number of subjects: 0
Study 8127531 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (20 micrograms ethinyl estradiol plus 0.15 mg desogestrel)
Number of subjects: 81
Study 8127531 — intervention group
Group type: COMPARATOR
Intervention: Oligomenorrheic women
Number of subjects: 81
Study 8127531 — intervention group
Group type: EXPERIMENTAL
Intervention: OC-treated women
Number of subjects: 81
Study 2758778 — intervention group
Group type: EXPERIMENTAL
Intervention: ADFR therapy (phosphorus 1.5 gr/day during 3 days, followed by SCT 100 UI/day during 10 days and calcium 1 gr/day)
Number of subjects: 100
Study 2758778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 412489 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% cromolyn sodium eye drops
Number of subjects: 14
Study 412489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30884195 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless transscleral intraocular lens (IOL) fixation
Number of subjects: 30
Study 30884195 — intervention group
Group type: COMPARATOR
Intervention: Retropupillary iris-claw lens fixation
Number of subjects: 30
Study 28326899 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicines (CAM) and non‐pharmacological interventions (NPI)
Number of subjects: 202638
Study 28326899 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal therapies
Number of subjects: 202638
Study 28326899 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins
Number of subjects: 202638
Study 28326899 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle approaches
Number of subjects: 202638
Study 28326899 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens
Number of subjects: 202638
Study 28326899 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education, Black ethnicity, MHT or previous oral contraceptive pill use
Number of subjects: 202638
Study 28326899 — intervention group
Group type: EXPERIMENTAL
Intervention: Less hopeful about their future
Number of subjects: 202638
Study 26383005 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein (SV) Y-composite grafts
Number of subjects: 116
Study 26383005 — intervention group
Group type: COMPARATOR
Intervention: Right internal thoracic artery (RITA) Y-composite grafts
Number of subjects: 116
Study 25034667 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA (Clarinol A‐80; n = 18)
Number of subjects: 34
Study 25034667 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; sunflower oil; n = 16)
Number of subjects: 34
Study 23083114 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone (PBZ) at 4.4 mg/kg PO q12h day 1, 2.2 mg/kg PO q12h for 4 days, 2.2 mg/kg PO q24h for 9 days
Number of subjects: 25
Study 23083114 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam at 0.6 mg/kg q24h, 1.8 mg/kg q24h, 3.0 mg/kg q24h
Number of subjects: 25
Study 23083114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 19552662 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)‐fortified salt intervention
Number of subjects: 0
Study 19552662 — intervention group
Group type: COMPARATOR
Intervention: Post-intervention surveillance
Number of subjects: 0
Study 19552662 — intervention group
Group type: COMPARATOR
Intervention: Detailed Mf survey and child antigenaemia (Ag) survey in 2006
Number of subjects: 0
Study 19552662 — intervention group
Group type: COMPARATOR
Intervention: Post-intervention findings
Number of subjects: 0
Study 19552662 — intervention group
Group type: COMPARATOR
Intervention: Long-term effects of DEC intervention
Number of subjects: 0
Study 19552662 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intervention measures
Number of subjects: 0
Study 17706714 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg orally twice daily)
Number of subjects: 236
Study 17706714 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (1 gm orally twice daily)
Number of subjects: 236
Study 17706714 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E plus Propionyl-L-carnitine (300 mg and 1 gm orally twice daily)
Number of subjects: 236
Study 17706714 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar regimen)
Number of subjects: 236
Study 15530629 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 6825
Study 11520815 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide with induction chemotherapy
Number of subjects: 100
Study 11520815 — intervention group
Group type: COMPARATOR
Intervention: Control group (induction chemotherapy without thalidomide)
Number of subjects: 100
Study 9765724 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine in combination with cisplatin
Number of subjects: 0
Study 9765724 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine alone
Number of subjects: 0
Study 8432129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural bupivacaine (0.5 percent)
Number of subjects: 20
Study 8432129 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 20
Study 2890666 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocturnal dosing
Number of subjects: 9
Study 2890666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg nocturnal dosing
Number of subjects: 9
Study 2890666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29947833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tirofiban injection and tirofiban injection via a TA catheter to the infarcted coronary artery after aspiration (Group A)
Number of subjects: 122
Study 29947833 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tirofiban injection only (Group B)
Number of subjects: 122
Study 28620891 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaratumab plus doxorubicin
Number of subjects: 0
Study 28620891 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 0
Study 27147391 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred intervention
Number of subjects: 32
Study 27147391 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 32
Study 24667994 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%/timolol 0.5% preservative-free (PF) ophthalmic solution
Number of subjects: 561
Study 24667994 — intervention group
Group type: COMPARATOR
Intervention: Bimatoprost 0.03%/timolol 0.5% ophthalmic solution
Number of subjects: 561
Study 22641790 — intervention group
Group type: EXPERIMENTAL
Intervention: FLU-FOBT Program (linking FOBT provision to influenza vaccination)
Number of subjects: 41
Study 22641790 — intervention group
Group type: EXPERIMENTAL
Intervention: FLU-FOBT Program
Number of subjects: 41
Study 19902242 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 15
Study 19902242 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength exercise
Number of subjects: 15
Study 19902242 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 15
Study 18792649 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Stroop task
Number of subjects: 0
Study 18792649 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion Stroop task
Number of subjects: 0
Study 15682562 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiZen (polysorbate 80 0.5%)
Number of subjects: 50
Study 15682562 — intervention group
Group type: COMPARATOR
Intervention: Visine Original (tetrahydrozoline HCl 0.05%)
Number of subjects: 50
Study 12870162 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (metformin 400 to 2,400 mg/d + glibenclamide 2.5 to 15 mg/d)
Number of subjects: 88
Study 12870162 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone (500 to 3,000 mg/d)
Number of subjects: 88
Study 12870162 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide alone (5 to 15 mg/d)
Number of subjects: 88
Study 12870162 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment vs Metformin alone
Number of subjects: 88
Study 12870162 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment vs Glibenclamide alone
Number of subjects: 88
Study 10510105 — intervention group
Group type: EXPERIMENTAL
Intervention: SR alfuzosin (5 mg twice daily)
Number of subjects: 81
Study 10510105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 10510105 — intervention group
Group type: EXPERIMENTAL
Intervention: SR alfuzosin
Number of subjects: 81
Study 9071060 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative and novel activity presentations
Number of subjects: 315
Study 9071060 — intervention group
Group type: COMPARATOR
Intervention: Traditional drug abuse prevention program activities
Number of subjects: 315
Study 1568518 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifamycin SV (525 mg weekly for 10 weeks)
Number of subjects: 40
Study 1568518 — intervention group
Group type: COMPARATOR
Intervention: Pefloxacin (560 mg weekly for 10 weeks)
Number of subjects: 40
Study 1568518 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Rifamycin SV vs Pefloxacin
Number of subjects: 40
Study 3902550 — intervention group
Group type: EXPERIMENTAL
Intervention: Golytely preparation
Number of subjects: 70
Study 3902550 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation
Number of subjects: 70
Study 31337413 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Clubs intervention
Number of subjects: 0
Study 31337413 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29342492 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA combined with biliary stenting (RFA + stent group; n = 32)
Number of subjects: 65
Study 29342492 — intervention group
Group type: COMPARATOR
Intervention: Biliary stent only (stent‐only group; n = 33)
Number of subjects: 65
Study 29342492 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA combined with biliary stenting (RFA + stent group)
Number of subjects: 65
Study 29342492 — intervention group
Group type: COMPARATOR
Intervention: Biliary stent only (stent‐only group)
Number of subjects: 65
Study 29342492 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study 27268605 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard interferon (IFN) therapy combined with ribavirin (3 MIU three times a week and 800-1200 mg/day) for six months
Number of subjects: 51
Study 26244389 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 141
Study 26244389 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted protease inhibitor (PI/r)
Number of subjects: 141
Study 26244389 — intervention group
Group type: EXPERIMENTAL
Intervention: X4 HIV variants
Number of subjects: 141
Study 23711611 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 706
Study 23711611 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 706
Study 20625011 — intervention group
Group type: EXPERIMENTAL
Intervention: couple‐focused Eban HIV/STD risk‐reduction intervention
Number of subjects: 1070
Study 20625011 — intervention group
Group type: COMPARATOR
Intervention: attention‐matched individual‐focused health promotion comparison
Number of subjects: 1070
Study 18431575 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-Bopta
Number of subjects: 10
Study 18431575 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-Dota
Number of subjects: 10
Study 18431575 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contrast materials
Number of subjects: 10
Study 16637753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fearful faces
Number of subjects: 0
Study 16637753 — intervention group
Group type: COMPARATOR
Intervention: Happy faces
Number of subjects: 0
Study 16637753 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety levels
Number of subjects: 0
Study 12783630 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol CR (Innopran XL) 160 mg single dose at 10 pm
Number of subjects: 0
Study 12783630 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release propranolol, single dose
Number of subjects: 0
Study 12783630 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol CR and sustained-release propranolol, multiple dosing
Number of subjects: 0
Study 12783630 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol CR and sustained-release propranolol, final dose
Number of subjects: 0
Study 12783630 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol CR and sustained-release propranolol, bioavailability
Number of subjects: 0
Study 11186500 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-managed group
Number of subjects: 317
Study 11186500 — intervention group
Group type: COMPARATOR
Intervention: Regular-care group
Number of subjects: 317
Study 8784645 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine (dosage not specified, administered twice or three times daily)
Number of subjects: 0
Study 8784645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1312853 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 8
Study 1312853 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg, twice daily for 5 days (pretreatment)
Number of subjects: 8
Study 6547414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g 4 times daily for 8 weeks)
Number of subjects: 30
Study 6547414 — intervention group
Group type: COMPARATOR
Intervention: Carbenoxolone (50 mg 4 times daily for 8 weeks)
Number of subjects: 30
Study 31046174 — intervention group
Group type: EXPERIMENTAL
Intervention: 3Q-positives (individuals who screened positive to at least one of the 3Q/TMD questions)
Number of subjects: 300
Study 31046174 — intervention group
Group type: EXPERIMENTAL
Intervention: 3Q-positives
Number of subjects: 300
Study 31046174 — intervention group
Group type: COMPARATOR
Intervention: 3Q-negatives (age and gender matched control group)
Number of subjects: 300
Study 28939682 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (target 45 mg daily)
Number of subjects: 3398
Study 28939682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3398
Study 28939682 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Pioglitazone and Placebo
Number of subjects: 3398
Study 27402183 — intervention group
Group type: EXPERIMENTAL
Intervention: Xbox Kinect™ activities (15min) + self‐directed physiotherapy exercises (15min)
Number of subjects: 30
Study 27402183 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (self‐directed exercises for 30min)
Number of subjects: 30
Study 27402183 — intervention group
Group type: EXPERIMENTAL
Intervention: Xbox Kinect™ activities + self‐directed physiotherapy exercises
Number of subjects: 30
Study 27402183 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 30